Ainos, Inc.
AIMD
Rank in Stocks
#30765
Ainos, Inc. operates as a healthcare technology company, specializing in... Ainos, Inc. operates as a healthcare technology company, specializing in point-of-care diagnostics and the development of safe, novel treatments for various disease indications. Its current portfolio encompasses a COVID-19 antigen rapid test kit, which integrates with a cloud-based test management platform known as the Ainos App, offering both personal and enterprise applications. Other diagnostic developments include a COVID-19 nucleic acid test and point-of-care testing for volatile organic compounds. Furthermore, the company is progressing with Very Low-Dose Oral Interferon Alpha, an oral formulation engineered to leverage the wide therapeutic applications of IFN-a, and is actively developing a Synthetic RNA (sRNA) technology platform in Taiwan. Established in 1984, this San Diego, California-based firm was formerly known as Amarillo Biosciences, Inc. until its rebranding to Ainos, Inc. in May 2021.
Share Price
$0.6
Last synced: 2026-11-09
Market Cap
$4.43M
Change (1 day)
-14.04%
Change (1 year)
-80.77%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Ainos, Inc. (AIMD)
Category
Healthcare
EPS for Ainos, Inc. (AIMD)
EPS as of June 2026 TTM: $-2.52
According to Ainos, Inc.'s latest financial reports, its current EPS (TTM) is $-2.52. At the end of 2025 the company had an EPS of $-3.46, a decrease compared to its 2024 EPS of $-1.56.
EPS history for Ainos, Inc. from 2000 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-2.52 | -27.17% |
| 2025 | $-3.46 | 121.79% |
| 2024 | $-1.56 | -53.57% |
| 2023 | $-3.36 | -34.63% |
| 2022 | $-5.14 | 98.46% |
| 2021 | $-2.59 | -3.72% |
| 2020 | $-2.69 | 263.51% |
| 2019 | $-0.74 | 32.14% |
| 2018 | $-0.56 | 36.59% |
| 2017 | $-0.41 | -18.00% |
| 2016 | $-0.50 | 28.21% |
| 2015 | $-0.39 | -53.01% |
| 2014 | $-0.83 | -65.70% |
| 2013 | $-2.42 | -4.35% |
| 2012 | $-2.53 | -56.08% |
| 2011 | $-5.76 | -302.11% |
| 2010 | $2.85 | -114.23% |
| 2009 | $-20.03 | 13.48% |
| 2008 | $-17.65 | -34.34% |
| 2007 | $-26.88 | -23.68% |
| 2006 | $-35.22 | 204.67% |
| 2005 | $-11.56 | -15.19% |
| 2004 | $-13.63 | -339.12% |
| 2003 | $5.70 | -125.12% |
| 2002 | $-22.69 | 29.81% |
| 2001 | $-17.48 | -86.06% |
| 2000 | $-125.43 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -721.43% |
US
|
|
| $-7.07 | 180.56% |
US
|
|
| $-5.29 | 109.92% |
AU
|
|
| $12.88 | -611.12% |
BE
|
|
| $21.56 | -955.56% |
NL
|
Questions about Ainos, Inc.'s earnings per share (EPS)
What is Ainos, Inc.'s earnings per share (EPS)?
Ainos, Inc.'s earnings per share (EPS) over the last twelve months is $-2.52, as of Jun 2026.
What was Ainos, Inc.'s earnings per share (EPS) in 2025?
In 2025, Ainos, Inc.'s earnings per share (EPS) was $-3.46, compared with $-1.56 in 2024.
How has Ainos, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Ainos, Inc.'s earnings per share (EPS) was highest in 2024 ($-1.56) and lowest in 2022 ($-5.14).
How does Ainos, Inc.'s earnings per share (EPS) compare with similar companies?
Ainos, Inc.'s earnings per share (EPS) ($-2.52) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.